The company's principal activity is to develop medicines for serious diseases from genomics and natural products. the research and development efforts of the company are focused on anti-angiogenesis, respiratory diseases, obesity, and infectious diseases. the products of the company include squalamine which is the lead product candidate in anti-angiogenesis. trodulamine, formerly known as produlestan, is the company's second natural aminosterol product. the company has maintained a respiratory product development program designed to discover and develop treatment alternatives for respiratory diseases. in addition to squalamine and trodulamine, discovery of natural aminosterols has been complemented by a combinatorial chemistry and biology program that has produced many synthetic aminosterols. during 2001, the company changed its name from magainin pharmaceuticals inc. to genaera corporation.